Allucent has introduced the Integrated Global Network for Innovative Trial Execution (IGNITE) aimed at improving speed, quality as well as predictability across clinical trial delivery.
The network encompasses over 250 pre-qualified clinical research sites and is intended to facilitate faster site activation, improved patient recruitment, and reduced risk in the development process.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It is part of Allucent’s approach to connect trial sponsors with research sites that correspond to its therapeutic centres of expertise.
These include areas such as oncology and haematology, neuroscience, cardiometabolic diseases, immunology and inflammation, infectious diseases, and rare diseases.
Rather than relying on site selection on a study-by-study basis, IGNITE is structured on long-term strategic partnerships to bring together specialist investigators familiar with complex clinical programmes.
Allucent stated that IGNITE offers sponsors access to feasibility assessments within 72 hours and pre-qualified sites adhering to defined activation timelines.
In North America, the network commits to site activation within 60 days of final protocol, and internationally within three to four weeks following regulatory approval.
According to the company, this framework aims to allow sponsors to progress from protocol approval to patient screening, providing support from initial enrolment through to completion of trials.
The company said both trial sponsors and site partners stand to benefit, with sponsors gaining access to experienced investigators and patient populations estimated to represent over 50 million individuals relevant to the targeted therapeutic areas.
Participating sites are said to benefit from earlier involvement in studies and alignment with research within their expertise.
Allucent chief operating officer Patrick Phillips said: “IGNITE brings together proven site partners, therapeutic expertise, and clear operational commitments to help sponsors move from protocol to patient enrolment faster and with greater predictability.
“It’s a differentiated approach that creates stronger alignment across sponsors, sites, and patients, helping reduce execution risk and improve trial predictability.”
Allucent indicated that the IGNITE initiative integrates its therapeutic expertise, technology and AI capabilities, site strategy, and global operational model to address increasing complexity in drug development for emerging biopharma firms.
